Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Multiple Sclerosis Centers of Excellence

Menu
Menu
Quick Links
Veterans Crisis Line Badge
My healthevet badge
 

Alemtuzumab (Lemtrada)

Alemtuzumab (Lemtrada) is a medication administered by two IV infusions, separated by one year, for the treatment of relapsing forms of MS. Alemtuzumab binds to CD52, a cell surface antigen present on T and B lymphocytes, and on natural killer cells, monocytes, and macrophages. Following cell surface binding to T and B lymphocytes, alemtuzumab results in antibody-dependent cellular cytolysis and complement-mediated lysis. Because of its safety profile, the use of alemtuzumab should generally be reserved for people who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Additional Information

Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.

return to top go